DECHENG CAPITAL LLC
Q4 2023 Form 13-F
MENLO PARK, CAYMAN ISLANDS
CIK 0002010850
· CRD 293073
· SEC-registered investment adviser
$357.9M Reported Value Total
DC GLOBAL VENTURES reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $1,802,579,659, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
8 funds
· $2.7B gross asset value
Venture Capital Fund: $2.5B · Hedge Fund: $228.2M
Source: Form ADV filed 2026-03-31
Reported value
$357.9M
Quarter over quarter
0.0%
Holdings
24
Top-10 concentration
84.6%
Key People
Form ADV owners & control persons
Xiangmin Nmn Cui
MANAGING DIRECTOR
Hongbo Nmn Bao
CHIEF COMPLIANCE OFFICER
Yuheng Nmn Qiu
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2023 13F record
Q4 2023 13F filing summary
| Period of report | December 31, 2023 |
|---|---|
| Filed | February 12, 2024 |
| Form | 13F-HR |
| Reported value | $357.9M |
| Positions | 24 |
| Change in reported value | First reported quarter |
| Top-10 concentration | 84.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
11 | $685.1M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
14 | $731.7M |
|
Q1 2026 13F
Filed May 13, 2026
|
14 | $661.3M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
19 | $743.4M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
23 | $573.2M |
|
Q2 2025 13F
Filed Aug 13, 2025
|
25 | $396.0M |
|
Q1 2025 13F
Filed May 8, 2025
|
27 | $356.5M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
28 | $466.2M |
|
Q3 2024 13F
Filed Nov 15, 2024
|
26 | $422.2M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
24 | $326.3M |
|
Q1 2024 13F
Filed May 14, 2024
|
22 | $745.6M |
|
Q4 2023 13F
Filed Feb 12, 2024
|
24 | $357.9M |
Top 20 holdings · Q4 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ALPN Alpine Immune Sciences, Inc. | $135.0M | 37.72% |
| 2 | ZNTL Zentalis Pharmaceuticals Inc. | $31.8M | 8.89% |
| 3 | PACB Pacific Biosciences of California, Inc. | $28.8M | 8.06% |
| 4 | TXG 10x Genomics, Inc. | $20.1M | 5.62% |
| 5 | IMGN IMMUNOGEN INC | $19.6M | 5.47% |
| 6 | RCUS Arcus Biosciences, Inc | $16.6M | 4.64% |
| 7 | KRTX KARUNA THERAPEUTICS INC | $14.9M | 4.16% |
| 8 | ROIV ROIVANT SCIENCES LTD | $14.4M | 4.02% |
| 9 | ILMN Illumnia, Inc. | $11.3M | 3.15% |
| 10 | ARGX Argenx SE | $10.4M | 2.92% |
| 11 | SLRN ACELYRIN INC(NSM) | $10.2M | 2.86% |
| 12 | KRYS KRYSTAL BIOTECH INC | $8.2M | 2.28% |
| 13 | PHAT PHATHOM PHARMACEUTICALS INC | $7.8M | 2.17% |
| 14 | LNTH LANTHEUS HOLDINGS INC(NMS) | $5.7M | 1.6% |
| 15 | TERN Terns Pharmaceuticals, Inc. | $4.6M | 1.3% |
| 16 | AURA Aura Biosciences, Inc. | $4.6M | 1.28% |
| 17 | BYSI BeyondSpring Inc. | $4.5M | 1.24% |
| 18 | EQ Equillium Inc. | $3.2M | 0.9% |
| 19 | ATRC AtriCure Inc. | $1.7M | 0.46% |
| 20 | HLTH Cue Health Inc. | $1.5M | 0.41% |
Values as reported on the Q4 2023 Form 13F. Every position is in the holdings table below.